An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia

Objective: Trastuzumab (Herceptin®), a recombinant, humanized, monoclonal antibody targeting HER2 is well established as an effective treatment for HER2-positive breast cancer. Evidence from developed countries showed that trastuzumab was cost-effective; but there are few evidences in developing cou...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Biomédica
Hoofdauteurs: Jefferson Antonio Buendía, Carlos Vallejos, Andrés Pichón-Rivière
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Instituto Nacional de Salud 2013
Onderwerpen:
Medicina
Positive
Colombia
Breast cancer
Human Epidermal Growth Factor Receptor 2
Online toegang:https://www.redalyc.org/articulo.oa?id=84329151010
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items